ArticleInternational journal of clinical pharmacy2024
Impact and implications of national centralized drug procurement in China.
Article in International journal of clinical pharmacy, 2024. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 15 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
15 citing papers in PubMed.
- Impact of national volume-based procurement on physicians' antimicrobial prescribing behaviours: an interrupted time series analysis of 1200 prescriptions in a tertiary hospital.Annals of medicine · 2026Article
- Workload and personnel allocation in pharmacy departments of public hospitals in China: a current state study.Scientific reports · 2026Article
- Analysis of the impact of national centralized volume-based procurement drug policy on the market dynamics of tuberculosis drugs.BMC health services research · 2026Article
- Patient Priorities for Coverage of New Antihypertensive Drugs: A Discrete Choice Experiment in China.Patient preference and adherence · 2026Article
- Optimizing PD-1/PD-L1 inhibitors plus chemotherapy for driver mutation-negative non-squamous NSCLC in China: a cost-effectiveness analysis.Frontiers in pharmacology · 2026Article
- Article
- Impact of combined medication payment management policies on population health performance.PloS one · 2026Article
- Prevalence and Intensity of Catastrophic Health Expenditure Among Residents in a Multiethnic Province in China: Cross-Sectional Study.JMIR public health and surveillance · 2025Article
- Observational
- Knowledge, attitudes, and practices of outpatients regarding National centralized drug procurement policy: a multicenter cross-sectional study in North China.Scientific reports · 2025Article
- Optimizing clinical nutrition practices: impact of a formulary prescription-based nutrition therapy protocol in surgical patients.Frontiers in nutrition · 2025Article
- Trends in Combinatorial Endocrine Therapy for Breast Cancer Across Six Cities in China(2016-2021).Risk management and healthcare policy · 2025Article
- Cost shifting or cost cutting by hospitals as a response to reimbursement reform? The case of diagnosis-related groups (DRG) scheme in China.Frontiers in public health · 2025Article
- Impact of China's National Volume-Based Procurement policy exclusively for insulin on the volume, expenditure and price: an interrupted time series analysis in Guangdong Province.Frontiers in public health · 2025Article
- Comorbidity and cost burden among ischemic stroke inpatients aged 60 years and older in middle-high-income region in China: a multicenter cross-sectional study.Frontiers in public health · 2025Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
5 authors.
Funding
Abstract
The national centralized drug procurement (NCDP) policy, known as the "4 + 7" policy in China, has transformed pharmaceutical procurement and access by leveraging healthcare institutions' collective buying power to reduce drug prices substantially. This policy has profoundly impacted drug pricing mechanisms, healthcare expenditures, market dynamics, and the quality of available drugs. This commentary evaluates the efficacy, challenges, and broader implications of the NCDP, summarizes the current state of post-marketing monitoring of selected generic drugs for centralized procurement, and presents relevant considerations.
Indexed as
Identifiers
38990456What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.